The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Shop Purgo Labs

Retatrutide vs Ozempic

Retatrutide vs Ozempic (semaglutide): triple agonist vs pure GLP-1 agonist. Phase 3 data shows retatrutide produces approximately 24.2% weight loss vs 14.9% for semaglutide — a difference of roughly 9 percentage points.

Weight Loss Comparison

Semaglutide (STEP-1): 14.9% weight loss at 68 weeks. Retatrutide (TRIUMPH-1): 24.2% at 48 weeks. For a 250 lb subject, this represents approximately 37 lbs (semaglutide) vs 60 lbs (retatrutide) of weight loss.

Mechanism Difference

Semaglutide: GLP-1 receptor agonism only. Retatrutide: GLP-1 + GIP + glucagon triple agonism. The glucagon component is the key differentiator — it increases energy expenditure and hepatic fat reduction beyond what GLP-1/GIP dual agonism achieves.

Regulatory Status

Ozempic/Wegovy (semaglutide): FDA-approved. Retatrutide: Phase 3 trials ongoing, not yet approved. Semaglutide is the appropriate choice for any protocol requiring an FDA-approved compound.